MedTrace Logo

RegisterPROS - a Registry for Prostate Cancers

NCT06872619 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-03-12

No results posted yet for this study

Summary

Prostate cancers are derived from epithelial cells in the prostate gland. Treatment options include surgery, medical (androgen signaling targeted and chemotherapy) and radiation therapy including radioligand therapy (RLT). Survival is linked to early and accurate diagnoses or to the effective detection of disease recurrence and/or treatment failure. One challenge is to develop accurate non-invasive tests that can detect prostate cancer disease activity. A second challenge is to evaluate the effectiveness of such biomarkers during the natural history of this disease (e.g., active surveillance). A third aim is to identify whether molecular markers can predict response to different therapies (either pre-treatment, or early on during the first few cycles of a therapy). RegisterPROS registry aims at collecting data and blood samples from patients being evaluated for PCa disease. Data will be entered prospectively and anonymized after informed consent. All physicians who treat PCas are invited to participate to the registry. Data will be evaluated within regular time frames, focusing on diagnostic accuracy for biomarkers in the different types of tumors, treatment modalities and patient outcomes (e.g. disease recurrence and survival), thereby contributing to an understanding of the role of biomarkers in tumor management.

Conditions

  • Prostate Cancer (Adenocarcinoma)
  • Prostate Biopsy
  • Prostatectomy
  • Radioligand
  • Chemotherapy
  • Androgen Deprivation Therapy
  • PSA

Interventions

DEVICE

PROSTest

Multianalyte Algorithm Analysis of circulating prostate cancer transcripts

Sponsors & Collaborators

  • Münster University Hospital, Germany

    collaborator UNKNOWN

  • Wren Laboratories LLC

    lead INDUSTRY

Principal Investigators

  • Abdel Halim, PhD, PharmD · Wren Laboratories

  • Kambiz Rahbar, MD · Munster University Hospital

Eligibility

Min Age
45 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-15
Primary Completion
2025-12-15
Completion
2030-12-15

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06872619 on ClinicalTrials.gov